Peptidylarginine deiminase 2 (PAD2/PADI2) has been implicated in various inflammatory diseases, and more recently, cancer. The goal of this study was to test the hypothesis that PAD2 promotes oncogenesis using a transgenic mouse model. We found that ~37% of transgenic mice overexpressing human FLAG-PAD2 downstream of the MMTV-LTR promoter develop spontaneous neoplastic skin lesions. Molecular and histopathological analysis of the resulting lesions finds that they contain increased levels of markers for invasion, inflammation, and EMT, and that a subset of the lesions progress to invasive squamous cell carcinoma (SCC). We then stably overexpressed FLAG-PAD2 in the human SCC cell line, A431, and found that the PAD2 overexpressing cells were more tumorigenic in vitro, and also contained elevated levels of markers for inflammation and EMT.
Introduction
The peptidylarginine deiminase (PADI, or more commonly referred to as PAD) family of posttranslational modification enzymes converts positively charged arginine residues on substrate proteins to neutrally charged citrulline. This activity, alternatively called deimination or citrullination, has been shown to have wide-ranging effects on target protein structure, function, and protein-protein interactions. Increasingly, the dysregulation of PAD activity is associated with a range of diseases, including rheumatoid arthritis (RA), multiple sclerosis, ulcerative colitis, neural degeneration, COPD, and cancer (1) (2) (3) . While the presumptive function of PAD activity in most diseases is linked to inflammation, the role that PADs play in cancer progression is still under investigation (4) (5) (6) (7) . Our recent studies suggest a role for PAD2 in the oncogenic progression of breast cancer (8) (9) (10) (11) and provide preclinical evidence showing that the PAD inhibitor, Cl-amidine, could be utilized as a therapeutic agent for the treatment of tumors in vivo (11) . To further investigate the involvement of PAD2 in the oncogenesis of epithelial tumors, we generated FVB/N mice expressing FLAG-PAD2 under the control of the mammary tumor virus (MMTV) promoter. As with previous studies (12, 13) , we found that the MMTV promoter drives transgene expression in a range of tissues, including the mammary gland, salivary gland, ovaries, and skin. Results from our spontaneous tumor study show that ~37% of the PAD2 transgenic mice developed skin lesions within a period of 4-12 months after birth. These tumors expressed high levels of transgenic human PAD2 and display markers of increased invasiveness and epithelial-to-mesenchymal transition (EMT). Furthermore, a subset of these tumors displays the hallmarks of malignant progression to highly invasive squamous cell carcinomas. The findings identify a novel genetic mouse model of skin neoplasia and define a role for PAD2 in cancer progression.
Materials and Methods

Generation of MMTV-FLAG-PAD2 mice
To generate the MMTV-FLAG-PAD2 construct, human PAD2 cDNA was subcloned from pcDNA3.1-FLAG-PAD2 (14) into the EcoRI sites of the MMTV-SV40-Bssk plasmid (Addgene plasmid #1824), originally generated in the laboratory of Dr. Philip Leder at Harvard Medical School (15) . The linear MMTV-FLAG-PAD2 construct was purified and microinjected into the pronuclei of fertilized embryos from super-ovulated FVB/N (FVB/NJ, JAX) mice, and 2-cell stage embryos were transferred to pseudopregnant mothers. The microinjection and embryo transfer were performed by the Stem Cell and Transgenics Core at Cornell University's College of Veterinary Medicine. Mice were genotyped for the presence of an integrated human PAD2 transgene by PCR with the primers hPAD2-cds-F/R, and mouse Pad4 was used as genomic control (see Supplementary Table 1 ). All mouse experiments were reviewed and approved by the Institutional Animal Care and Use Committees (IACUC) at Cornell University.
Stable FLAG-PAD2 expression in A431 cells
The human squamous cell carcinoma (SCC) A431 cell line was obtained from ATCC (CRL-1555) in 2013, and cultured according to manufacturer's directions for 2-weeks prior to the generation of stable lines. Authentication was performed by ATCC using short tandem repeat (STR) DNA fingerprinting (16) . To generate A431 cells overexpressing FLAG-tagged PAD2, two separate plasmids were generated by subcloning FLAG-PAD2 into the pIRES2-EGFP vector (Clontech) and pLenti-PGK-GFPPuro plasmid (Addgene #19070), followed by transfection and transduction, respectively (see
Supplementary Methods).
Immunohistochemistry (IHC) and immunofluorescence (IF)
IHC and IF experiments were carried out using a standard protocol as previously described (9) . Primary antibodies are as follows: anti-PAD2 (12110-1-AP, ProteinTech), anti-FLAG-M2 (F1804, Sigma), antipan-Citrulline (ab6464, Abcam), anti-Ki67 (ab15580, Abcam), and anti-IL6 (ab6672, Abcam). Negative controls were either normal rabbit or mouse IgG.
Western blotting
Western blotting was carried out as previously described (9) . Primary antibodies against PAD2 (12110-1-AP, ProteinTech) and FLAG-M2 (F1804, Sigma) were incubated overnight at 4 o C. To confirm equal protein loading, membranes were stripped and re-probed with anti-β-actin (ab8227, Abcam).
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RNA isolation, semi-quantitative, and quantitative real-time PCR (qPCR)
RNA was purified using the Qiagen RNeasy kit, including on-column DNase treatment, and reversetranscribed using the Applied Biosystems High Capacity RNA-to-cDNA kit according to the manufacturer's protocol. See Supplementary Methods for a more detailed description of semiquantitative and qPCR, and Supplementary Tables 1-3 for primer sequences.
Assay for cellular malignancy and invasion
Collagen coated inserts for 24-well plate wells (Falcon BD Fluoroblok; #351152) were used to conduct transwell migration assays as previously described (17) , and further detailed in the Supplementary Methods. Focus formation assays were carried out as previously described (18) .
Statistical analysis
All experiments were independently repeated at least three times unless otherwise indicated. Values were expressed as the mean + the SD and analyzed using Student's t-test or Analysis of Variance (with Tukey's post hoc analysis) where three or more groups were compared to one another using continuous data. Incidence of spontaneous lesions in MMTV-FLAG-PAD2 mice was measured 4-12 months postbirth, along with age-matched FVB/N mice from the corresponding founder line. Data were analyzed using a chi-squared test with Yates correction for continuity. Significance was set at an alpha of 0.05.
Results
Generation of MMTV-FLAG-PAD2 transgenic mice
To assess the potential role of PAD2 in the oncogenesis of epithelial tissue, we generated a mouse model in which the human PAD2 gene is overexpressed under the control of the hormone-responsive MMTV-LTR promoter. The transgenic construct consists of an MMTV-LTR promoter placed upstream of the human FLAG-tagged PAD2 cDNA, followed by an SV40 splice/polyadenylation site ( Figure 1A) .
MMTV-FLAG-PAD2 mice were generated, and seven potential founders were tested for the presence of transgene by PCR. Four founders (4807, 4853, 4680, and 4863) were identified (indicated in red, Figure 1B ) that carried germline transmission of the FLAG-PAD2 transgene. We note that 4807 was not included in subsequent analyses due to poor breeding. Using semi-quantitative RT-PCR, we confirmed the presence of FLAG-PAD2 transcript in the skin, salivary gland, mammary gland, and ovary of the transgenic mice ( Figure 1C) . These four tissues were chosen for analysis because they have previously been shown to express high levels of MMTV-LTR-driven transgenes (13) . Quantitative real-time PCR analysis (qPCR) of the same tissues demonstrated that, while PAD2 expression was highest in salivary and mammary glands, significant levels of transgenic PAD2 were also found in the skin of all three founders (P < 0.01) ( Figure 1D ). We note here that, while transgenic expression of hPAD2 was observed in the mammary glands of both virgin (Supplementary Figure 1A) and multiparous mice (Supplementary Figure 1B) , we did not detect any gross abnormalities or any observable phenotype in the mammary glands of these mice. The potential mechanisms that may be blocking PAD2-mediated oncogenesis in the mammary gland are currently being investigated.
PAD2 transgenic mice develop skin lesions with the potential to advance to invasive squamous cell carcinomas
Analysis of spontaneous neoplastic growth in experimental mice found that ~37% of the mice across all founder lines developed skin lesions between 4-12 months of age ( Table 1) . When compared to agematched wild-type FVB/N mice, the increased rate of neoplastic growth in FLAG-PAD2 transgenic mice was highly significant (χ 2 = 30.65; P < 0.001), suggesting that the PAD2 transgene is likely promoting oncogenesis. The percentage of males developing tumors was ~44%, while females developed tumors at a rate of ~56%, which was not significantly different across genders. These lesions occurred on both the dorsum and ventrum of transgenic mice and are characterized by gross abnormalities, such as alopecia, multifocal epidermal ulceration often covered in sero-cellular crust, dysplasia, and thickening of the adjacent epidermis (Figure 2A ).
Histological evaluation of skin lesions from PAD2 overexpressing mice by H&E reveals that these sites contain highly neoplastic tissue, having features consistent with invasive SCC. We found nests of neoplastic cells which appeared to originate from the epidermis and invade into the dermis and subcutis ( Figure 2B, i and ii) ; moreover, the epidermis overlying the neoplasm was extensively ulcerated and frequently adjacent to hyperplastic epidermal layers ( Figure 2B, i) . Additionally, we observed that concentric layers of keratin surrounded tumor cells forming keratin pearls, which are characteristic of SCC ( Figure 2B , ii). We found that tumor borders were poorly defined, often with highly anaplastic tumor cells invading the deeper dermis and subcutis, and that neoplastic cells frequently infiltrated and separated skeletal myofibers (Figure 2B, iii) . The nests and islands of neoplastic cells within the subcutis showed a high degree of anisokaryosis and anisocytosis, with the nuclei often containing one to two prominent nucleoli ( Figure 2B, iv) . Clusters of neoplastic cells were found to be surrounded by loose collagenous stroma with a marked loss of adnexal structures, consistent with desmoplastic response ( Figure 2B , ii-iv). Lastly, we observed that these lesions often contained carcinoma cells budding from the primary neoplasm ( Figure 2B , iv), again indicating an invasive component to these tumors.
Recombinant PAD2 is expressed in the skin and tumor tissue of PAD2 transgenic mice
In order to test whether the observed skin neoplasia in the transgenic mice was driven by overexpression of hPAD2, we next investigated PAD2 expression levels in these mice by immunohistochemistry (IHC).
We probed these tissues with an anti-human PAD2 antibody and found that PAD2 protein was observed in the hyperplastic epidermis, neoplastic islands, and in the hair follicular epithelium ( Figure 2C , i).
Additionally, we observed high PAD2 expression in the neoplastic epithelium surrounding keratin pearls ( Figure 2C , ii and iii). PAD2 was also expressed in the invasive, budding nests of carcinoma cells, which appeared to invade stromal tissue adjacent to the primary neoplasm. (Figure 2C , iv). In order to test whether PAD2 overexpression correlated with increased deimination activity, we next probed sections from wild-type skin and transgenic PAD2 lesions with a pan-citrulline antibody that has been previously shown to specifically detect citrullinated proteins (19, 20) . Results show that the skin lesions from MMTV-FLAG-PAD2 mice appear to have increased pan-citrulline staining when compared to wild-type skin ( Figure 2D) , with the most intense levels of citrullination appearing to occur in the hyperplastic regions. Additionally, we found strong nuclear anti-pan-citrulline staining in these lesions ( Figure 2D , inset bottom image), which is in line with our previous studies showing that PAD2-mediated histone deimination regulates gene expression (9, 10, 14, 21) . Because the anti-human PAD2
antibody likely cross-reacts with endogenous mouse PAD2, we also stained these tissues with an anti- FLAG antibody to specifically stain the PAD2 fusion protein. We observed a similar expression pattern within the proliferating basal layers of hyperplastic/neoplastic epidermis, suggesting that much of the PAD2 signal originates from overexpression of the transgene (data not shown). We confirmed this prediction using indirect-immunofluorescence to co-stain for FLAG and PAD2 expression in the skin lesions of transgenic mice (Figure 3 ). PAD2 and FLAG were seen to both co-localize to the neoplastic epithelial cells ( Figure 3A , i-iv). While PAD2 shows strong staining in multiple layers of the epidermis, we found that FLAG-PAD2 expression is slightly more restricted to the basal layer, which is known to be more stem-cell like and highly proliferative (22) . Interestingly, we also see an apparent slight increase in the proliferative marker, Ki67, within the FLAG staining section of the SCC lesion ( Figure   3B , ii-iv). This observation supports the hypothesis that PAD2 overexpression in the skin promotes epidermal proliferation, which is further supported by the identification of a subset of lesions that are highly proliferative and characteristic of invasive SCC. We also note that control staining with rabbit Figure 2) and that the anti-FLAG antibody did not stain epidermal tissue from wild-type mice ( Figure 3C , i-vi) or adjacent normal skin from transgenic mice (data not shown).
IgG was negative (Supplementary
Enhanced inflammation marker expression is observed in the skin of transgenic mice when compared to wild-type skin and to the mammary gland of transgenic animals
Previous reports have implicated PAD2 in a wide-range of inflammation-associated diseases (23) (24) (25) , including our recent work where we reported that PAD2 appears to promote cancer progression in vitro and in vivo using a xenograft model of breast cancer (11) . Therefore, in an effort to identify potential pathways involved in the progression of MMTV-FLAG-PAD2 skin lesions, we next investigated the expression of a subset of inflammation and invasion-associated genes in the transgenic PAD2 lesions.
Interestingly, the lesions containing high levels of transgenic PAD2 (Figure 4A -C, lesions 2 and 4) also expressed high levels of Ki67, Il6, and the functional murine orthologs for human IL8; Cxcl1 (KC) (26), Cxcl2 (MIP-2) (27) , and Cxcl5 (LIX) (28) (P < 0.001) ( Figure 4D ). These lesions also expressed high levels of the inflammatory mediator, Cox2 (Figure 4E ), which has previously been shown to induce Il6 expression (29) . Additionally, these tumors also displayed elevated levels of the EMT markers, vimentin (Vim) and the E-cadherin repressor, Snail (Snai1, or more commonly referred to as Snail), along with decreased levels of E-cadherin (Cdh1, or hereafter Ecad) (P < 0.01) and GSK3β (Figure 4E ), which has been previously shown to be downregulated in SCCs of the tongue (30) and mouse models of skin tumorigenesis (31).
Our finding that PAD2 overexpression in the skin, but not the mammary gland, leads to neoplastic growth was somewhat surprising and we speculated that the lack of tumor growth in the mammary gland may have been due to a reduced ability of FLAG-PAD2 to promote inflammatory and/or EMT marker expression in this tissue. To test this hypothesis, we next examined inflammatory/EMT marker expression in skin and mammary gland from wild-type and transgenic mice.
Results show that, in large part, while PAD2 overexpression enhanced inflammatory marker expression in the skin, similar levels of induction were not observed in the mammary gland (Supplementary Figure 3) . These observations supported the hypothesis that PAD2 overexpression selectively promotes inflammatory marker expression and tumorigenesis in the skin but not the mammary gland. To test this hypothesis, we probed tissue sections with a well-validated anti-IL6 antibody. Results show that protein levels of Il6 appeared to be higher in the transgenic (TG) skin lesions when compared to the transgenic mammary gland and to wild-type (WT) skin ( Figure 4F) . Taken together, these findings suggest that, in the skin, PAD2 overexpression may enhance tumor progression by selectively promoting inflammation and by altering the invasive properties of epithelial cells. We also evaluated the effect of PAD2 overexpression on inflammatory and EMT marker expression in the salivary gland and found that EMT marker expression appeared to be dampened while inflammatory marker gene expression was not noticeably affected when compared to skin (Supplementary Figure 3) . Interestingly, there does not appear to be a direct PAD2 gene dosing effect with respect to inflammatory mediator/EMT expression in the different tumors and we predict that this discrepancy may be due to opposing and/or synergistic interactions between PAD2 and other PAD family members within individual tumors. In support of this prediction, we found that expression levels of PADs1-4 varied dramatically between tumors (Supplementary Figure 4B and C) . While speculative, it is possible that the ratio of PAD isozyme expression levels could modulate inflammatory/EMT expression levels and tumor growth and/or invasiveness to varying degrees. 
Overexpression of PAD2 in human SCC A431 cells increases invasiveness and malignancy
Outcomes from our transgenic MMTV-FLAG-PAD2 mouse study show that ectopic expression of PAD2 is sufficient to drive tumorigenesis in epithelial cells, and that this expression correlates with an increase in the expression of markers of inflammation and invasion. To test if PAD2 might play a similar role in humans, we next investigated whether PAD2 overexpression in the human skin cancer cell line, A431, might lead to a similar phenotype. This cell line functions as a model system for human SCC and was derived from a vulvular epidermoid carcinoma (32) . To investigate the oncogenic potential of PAD2 in these cells, we first transiently expressed FLAG-PAD2 using mammalian vectors (pcDNA3.1 and pIRES2) and found that these cell lines expressed high levels of the FLAG-PAD2 protein ( Figure 5A and 5B). Additionally, we found that PAD2 overexpression suppressed E-cadherin and increased vimentin protein expression when compared to A431 cells that had been transfected with an empty vector ( Figure 5A) . We next tested whether PAD2 overexpression altered the expression of inflammation and EMT markers and found that, similar to what was seen in transgenic mice, IL6 and IL8 gene levels were significantly increased in the PAD2 overexpressing cells, along with the inflammatory mediators COX2 and NFκB/RELA. Moreover, in addition to increasing the proliferation marker Ki67, we found that transient PAD2 overexpression also increased SNAIL and SLUG levels, while suppressing E-cadherin levels (P < 0.05) ( Figure 5C ). Lastly, we tested the effects of PAD2 overexpression on the expression of two proliferative oncogenes H-Ras (33, 34) and c-Myc (35) , which are known to be upregulated in skin carcinomas. Results show that levels of these oncogenes were unchanged in the PAD2 overexpressing cells, suggesting that the observed effects of PAD2 on oncogenesis are more direct in nature.
Given the data from our transiently transfected A431 cells, along with our data from the transgenic mice, we decided to investigate whether stable overexpression of FLAG-PAD2 might have an effect on the cellular malignancy and/or invasiveness of A431 cells. Using both lentiviral transduction of FLAG-PAD2, and traditional transfection, we created two stable PAD2 overexpressing lines: (1) pLenti-FLAG-PAD2 (pLenti-FP2), which expresses low levels of FLAG-PAD2; and (2) pIRES2-FLAG-PAD2 (pIRES-FP2), which expresses high levels of FLAG-PAD2 (Figure 6A and 6B) invasive properties of these cell lines by measuring their ability to migrate through a collagen matrix.
For both cell lines, we see a significant increase in cellular migration after 24h (P < 0.01), with the pIRES2-FP2 cell line also showing a significant increase in migration after only 4h (P < 0.01) ( Figure   6C ). These results suggest that PAD2 dosage might correlate with invasion. Finally, we wanted to examine the stable A431-pIRES2-FP2 cells for any increase in cellular malignancy. Assaying for focus formation, we show a significant increase in the FLAG-PAD2 overexpressing A431 cells compared to the empty vector control (P < 0.001) (Figure 6D ). In addition, we find that the morphology of these cells also displays an elongated, fibroblast-like shape, indicative of cells that have undergone EMT (Figure 6E) .
Discussion
In the present study, we demonstrate that transgenic overexpression of PAD2 in the epidermis promotes carcinoma formation in the skin. Additionally, we found that these lesions have the potential to advance to invasive SCC. These in vivo findings were supported by our in vitro studies, which showed that stable overexpression of PAD2 in the human SCC line, A431, resulted in increased cellular invasiveness and malignancy. At a more mechanistic level, we also demonstrate that PAD2 may promote carcinogenesis by enhancing the production of factors that promote inflammation and an EMT phenotype.
A number of mouse models, including models of advanced SCC, have documented a role for inflammation in cancer progression (36) . In humans, the links between inflammation and cancer are now so strong that inflammation is considered to be the seventh hallmark of cancer (36, 37) . Two key mediators of inflammation-driven cancers are the cytokines, IL6 and IL8, which promote cancer progression by stimulating tumor growth and angiogenesis (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) . Interestingly, a number of previous studies have documented a role for PAD2-mediated deimination in regulating inflammatory activities during disease progression (23, 24) . Additionally, PAD activity has also been found to regulate tissue inflammation via direct modification of IL8 (25) . Given these observations, we hypothesized that PAD2 may promote tumorigenesis by regulating the expression of IL6 and IL8. We tested this hypothesis and found that Il6 and IL8 ortholog expression is, in fact, increased in the skin lesions of PAD2 overexpressing mice, and that IL6 and IL8 expression is elevated in PAD2 overexpressing cells. In this study, we also show that PAD2 overexpression in transgenic mice, in addition to human A number of previous studies have shown that inflammatory cytokines, such as IL8, appear to promote cancer progression by inducing an EMT transition in tumor cells (41) . Thus, it is possible that PAD2 overexpression promotes cell invasiveness and an EMT phenotype by upregulating cytokine production in tumor cells. Interestingly, however, we recently reported that another PAD, PAD4, plays an important role in regulating an EMT transition in breast cancer cells via regulation of GSK3β-TGFβ signaling (50) . In that study, we found that PAD4 targets GSK3β for citrullination and that PAD4 depletion dramatically reduces levels of nuclear GSK3β, promotes an EMT transition, and increases tumor invasiveness. In the current study, we found that overexpression of PAD2 suppressed GSK3β expression, promotes an EMT phenotype and tumor growth. Together, these results raise the possibility that PAD2 and PAD4 may oppose or counterbalance each other in the maintenance of epithelial identity and in oncogenesis.
A surprising outcome of our project was that neoplastic growth appeared to be limited to the skin of PAD2 transgenic mice and was not observed in the mammary glands. While the ultimate explanation for this outcome is likely manifold, we found that the PAD2-mediated induction of inflammatory mediator expression was suppressed in the mammary glands of transgenic mice when compared to both the normal skin and the hyperplastic lesions from transgenic mice. These results suggest that, as opposed to the skin, a dampening mechanism may exist within the mammary gland which prevents FLAG-PAD2 from inducing inflammatory cytokine expression, thereby suppressing tumorigenesis. A potential 
overexpression in vivo appears to significantly modulate the expression of other PAD family members in both normal and tumor tissue (Supplementary Figure 4) . Therefore, while purely speculative, it is possible that the relatively low levels of FLAG-PAD2 that we observed in the skin promotes the expression of a specific ratio of PAD family members that is conducive to inflammation and tumorigenesis, while the relatively higher level of FLAG-PAD2 in the mammary gland alters this ratio, leading to reduced inflammatory mediator expression and an absence of neoplastic growth. Regarding the potential mechanisms by which PAD2 overexpression regulates gene activity, we have recently found that PAD2 functions as a transcription factor co-factor and modulates target gene expression via histone deimination at transcription factor binding sites (9, 10, 14, 21) . Therefore, we are currently testing the hypothesis that PAD2 regulates the expression of target genes via similar mechanisms.
In conclusion, this study demonstrates that overexpression of human PAD2 in mice and in human cell lines promotes carcinogenesis. Furthermore, we show that a subset of tumors in mice display hallmarks of malignant progression from skin lesions to highly invasive SCCs. Additionally, we demonstrate that PAD2 overexpression in vivo and in vitro enhances the expression of inflammatory cytokines and mediators of the epithelial-to-mesenchymal transition. Collectively, these studies provide functional and mechanistic evidence establishing PAD2 as a potential novel oncogene in the initiation and progression of epidermal carcinomas. Transgenic (MMTV-FLAG-PAD2) and age-matched wild-type FVB/N mice were observed over a period of 4-12 months post-birth, and spontaneous lesions were characterized by gross abnormalities, such as alopecia, multifocal epidermal ulceration (covered in sero-cellular crust), dysplasia, and thickening of the adjacent epidermis. Data were analyzed using a chi-squared test with Yates correction for continuity), χ 2 = 30.65, and P = <0.001. 
